While Seres Therapeutics Inc has underperformed by -4.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -37.11%, with highs and lows ranging from $2.05 to $0.54, whereas the simple moving average jumped by 0.55% in the last 200 days.
On October 24, 2024, JP Morgan Downgraded Seres Therapeutics Inc (NASDAQ: MCRB) to Underweight. JP Morgan also rated MCRB shares as ‘Neutral’, setting a target price of $7 on the company’s shares in an initiating report dated April 21, 2023. Goldman July 23, 2021d the rating to Sell on July 23, 2021, and set its price target from $24 to $7. Goldman initiated its ‘Neutral’ rating for MCRB, as published in its report on May 18, 2021. Chardan Capital Markets’s report from March 05, 2021 suggests a price prediction of $30 for MCRB shares, giving the stock a ‘Buy’ rating. Chardan Capital Markets also rated the stock as ‘Neutral’.
Analysis of Seres Therapeutics Inc (MCRB)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Seres Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -3758.21% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.12, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and MCRB is recording an average volume of 3.19M. On a monthly basis, the volatility of the stock is set at 8.93%, whereas on a weekly basis, it is put at 6.09%, with a loss of -3.70% over the past seven days. Furthermore, long-term investors anticipate a median target price of $3.31, showing growth from the present price of $0.89, which can serve as yet another indication of whether MCRB is worth investing in or should be passed over.
How Do You Analyze Seres Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 26.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 23.58% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
MCRB shares are owned by institutional investors to the tune of 23.58% at present.
